MP13-13 ANTIBIOTIC USE AND SURVIVAL OF PATIENTS RECEIVING PEMBROLIZUMAB FOR CHEMOTHERAPY-RESISTANT METASTATIC UROTHELIAL CARCINOMA

Yudai Ishiyama,Tsunenori Kondo,Yuki Nemoto,Yuki Kobari,Hiroki Ishihara,Hidekazu Tachibana,Kazuhiko Yoshida,Yasunobu Hashimoto,Toshio Takagi,Junpei Iizuka,Kazunari Tanabe

MP13-13 ANTIBIOTIC USE AND SURVIVAL OF PATIENTS RECEIVING PEMBROLIZUMAB FOR CHEMOTHERAPY-RESISTANT METASTATIC UROTHELIAL CARCINOMA

2021

Yudai Ishiyama
Tsunenori Kondo
Yuki Nemoto
Yuki Kobari
Hiroki Ishihara
Hidekazu Tachibana
Kazuhiko Yoshida
Yasunobu Hashimoto
Toshio Takagi
Junpei Iizuka
Kazunari Tanabe

INTRODUCTION AND OBJECTIVE:The use of antibiotics alters gut microbiota and has been reported to impact outcomes in immune checkpoint inhibitor (ICI) treatment in various types of cancer. We invest...

Keywords:

antibiotic use
Cancer research
Pembrolizumab
Metastatic Urothelial Carcinoma
Medicine
Cancer
Gut flora
chemotherapy resistant
Antibiotics
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations